This week, ZenPharm, the Maltese joint venture with Canadian cannabis producer, Zenabis Global, received its Maltese licence to process cannabis for medicinal use and research purposes out of its Hal Far Industrial Estate premises.
Kurt Farrugia, CEO of Malta Enterprise – the national economic development agency that assisted the company to set up locally – considers this “an important milestone for Malta’s medical cannabis industry.”
“We are gaining momentum with the production of cannabis for medical use in Malta,” he wrote. “Zenabis – a Maltese joint venture and partner of Zenpharm, have received a licence for the production of medical cannabis in their facility in Hal Far, Malta.”
The CEO said that the issuing of the second licence for the production of cannabis for medical use shows that “Malta is becoming a centre of excellence in such an important emerging sector.”
“Those companies strive hard to achieve the Medicine’s Authority pharmaceutical standards. Now that they do, patients can rest assured that the Made in Malta product is top quality. A gold standard for the industry. This is indeed a proud moment.”
Through its licence, ZenPharm plans to ship around 500kg of cannabis out of Malta annually to EU countries, with the largest market being Germany.
Featured Image:
Kurt Farrugia / LinkedIn
‘The best of GO is still ahead of us’: CEO Nikhil Patil as GO crosses €254 million revenue milestone
The company has just announced 'a milestone year on every front.'
Nearly 9 in 10 Maltese CEOs expect Iran conflict to impact business, PwC tracker finds
Global instability is beginning to temper sentiment.
Katrina Attard appointed to GO plc’s Board of Directors
Katrina Attard is the Chief Executive Officer of Panta Group.
€100m financing agreement ‘reflects confidence’ in Malta International Airport, says CEO
The company is currently undertaking the most significant upgrade to airport facilities since privatisation.
